Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Ilana Schlam MD, FACP

Ilana Schlam MD, FACP

Breast Medical Oncologist, Assistant Professor of Medicine, Tufts University Medical Center, Boston, MA

Ilana Schlam, MD is a breast medical oncologist and assistant professor of medicine at Tufts Univesity Medical Center. Dr. Schlam completed her medical school in Mexico, her home country. Then, she completed her internal medicine residency training at the Jewish Hospital of Cincinnati and her hematology and oncology training in MedStar Georgetown Washington Hospital Center in Washington, DC. Her research interests focus on precision medicine, drug development, and healthcare disparities in breast cancer.

Recent Contributions to PracticeUpdate:

  1. 2023 Top Story in Oncology: The POSITIVE Trial
  2. Efficacy of the Anthracycline-Free Neoadjuvant Regimen of Pembrolizumab and Carboplatin Plus Docetaxel in TNBC
  3. Outcomes of Palbociclib Rechallenge in Patients With HR+/HER2− Advanced Breast Cancer
  4. 2022 Top Story in Oncology: Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer—DESTINY-Breast04
  5. Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases
  6. Atezolizumab With Neoadjuvant Anti-HER2 Therapy and Chemotherapy in HER2-Positive Early Breast Cancer
  7. Elacestrant vs Standard Endocrine Therapy for ER+/HER2− Advanced Breast Cancer
  8. Neoadjuvant Treatment ± Atezolizumab in High-Risk TNBC

Most Read This Week

Recently Updated